Egpa - Open Access .click

Results 61 to 70 of about 8,038 (216)

Impact of Severe COVID‐19 on Interstitial Lung Disease in Autoimmune Systemic Diseases

Respirology Case Reports, Volume 14, Issue 9, September 2026.
In this multicentre case series of 27 patients with autoimmune systemic diseases, severe COVID‐19 pneumonia led to marked interstitial lung disease (ILD) worsening, with new‐onset or progressive ILD in all survivors and NSIP‐to‐UIP transition in six cases.
Clodoveo Ferri +95 more
wiley +1 more source

Nasal Airway Transcriptome Reflects Selected Asthma‐Associated Gene Signatures in the Lower Airways

Allergy, Volume 81, Issue 9, Page 3197-3205, September 2026.
Seven genes and two gene modules were consistently associated with asthma in both airway compartments in ARMS and were validated in ATLANTIS. The two modules reflected IL‐13 related inflammation and mast cell activity, respectively. Nasal gene signatures provide a non‐invasive proxy for selected bronchial asthma‐associated gene signatures. ARMS, Asthma
Hui Wen +22 more
wiley +1 more source

Az Eozinofil Granulomatosis Polyangiitissel (EGPA) patofiziológiája, diagnózisa és kezelése: The Pathophysiology, diagnosis, and treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA) [PDF]

: Eosinophilic Granulomatosis with Polyangiitis (EGPA), formerly known as Churg-Strauss syndrome, is a rare systemic vasculitis affecting small and medium-sized vessels, characterized by eosinophilia, asthma, and granulomatous inflammation.
Fodor, Bertalan, Varga, Rita
core +1 more source

Retention of a Patency Capsule Shell in a Nonsteroidal Anti‐Inflammatory Drug‐Induced Small‐Bowel Stricture, Detected and Retrieved by Balloon‐Assisted Enteroscopy: Emphasizing the Importance of Confirming Capsule Excretion

Journal of Digestive Diseases, EarlyView.
Shinichiro Kawatoko +4 more
wiley +1 more source

Remission in Global Airway Diseases: EUFOREA Consensus Paper

Allergy, Volume 81, Issue 9, Page 3146-3156, September 2026.
ABSTRACT The therapeutic goal in chronic airway diseases is shifting from symptom control to disease remission. Disease‐modifying therapies, including biologics and allergen immunotherapy, have made remission achievable in patients with severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), or allergic rhinitis (AR).
J. Christian Virchow +22 more
wiley +1 more source

Clinical manifestations of study patients with EGPA.

, 2015
EGPA: eosinophilic granulomatosis with polyangiitis (Churg-Strauss); BVAS: Birmingham Vasculitis Activity Score; BVAS/WG: BVAS for Wegener’s Granulomatosis; n (%), number and percentage of patients (out of those with known outcome) with manifestation ...
David Cuthbertson (188652) +14 more
core +1 more source

Once upon a time: the curious case of a backward story of EGPA [PDF]

Exploration of Asthma & Allergy
A high percentage of patients with severe asthma also suffer from nasal polyposis, with dupilumab, an anti-IL-4R antibody both diseases can be treated due to its role in type 2 (T2) inflammation.
Diego Bagnasco +10 more
doaj +1 more source

The 2025 ATS/ERS update of the international multidisciplinary classification of the interstitial pneumonias: implications for the pathologist

Histopathology, Volume 89, Issue 3, Page 403-425, September 2026.
This review highlights changes relevant to pathologists in the updated multidisciplinary classification of interstitial pneumonias. Changes include expansion beyond idiopathic disease, subclassification as interstitial (fibrotic vs non‐fibrotic) and alveolar filling disorders, expansion to include additional patterns (e.g.
Andrew G Nicholson +7 more
wiley +1 more source

Eosinophilic granulomatosis with polyangitis (eGPA)

, 2021
Summary: • Eosinophilic granulomatosis with polyangitis (eGPA or Churg-Strauss) o Presentation key features: > Orbital inflammatory syndrome • Redness, pain, lid edema, diplopia, ophthalmoplegia, optic neuropathy > Vasculitis-like presentation • Stroke o
Andrew G. Lee, MD; Nicole Weber
core

UpToDate on eosinophils [PDF]

Exploration of Asthma & Allergy
This review describes the eosinophil journey through the various physiological and pathophysiological phases, from production, maturation, and activation by chemokines and cytokines [especially eotaxin, interleukin (IL)-5, IL-3, and granulocyte ...
Mario Di Gioacchino +33 more
doaj +1 more source

eosinophilic granulomatosis with polyangiitis
asthma
mepolizumab

medicine
vasculitis
eosinophilia

benralizumab
anca-associated vasculitis
allergy